Glaukos Announces Third Quarter 2026 Financial Results
Glaukos posted record Q3 2026 net sales of $211.0 million, up 58% year-over-year, and swung to GAAP net income of $2.0 million ($0.03 diluted EPS) versus a $16.2 million loss a year ago. Both growth drivers accelerated: U.S. Glaucoma sales rose 47% to $118.6 million on iDose TR momentum, while Corneal Health jumped 154% to $59.0 million. Gross margin expanded to ~85% (88% non-GAAP), and the company ended the quarter with $339.8 million in cash and no debt.
Key figures
- Eps
- 0.03
- Revenue
- 211030000
- Guidance
- 2026 net sales raised to $775M-$785M (from $680M-$700M); preliminary 2027 net sales of $1 billion
- Revenue Yoy
- 58%
- Sga
- 130943000
- Debt
- 0
- Net income
- 2018000
- Rd expense
- 48095000
- Gross margin
- 85.2%
- Non gaap eps
- 0.47
- Operating income
- 828000
- Non gaap net income
- 28500000
- Cash and investments
- 339800000
- Non gaap gross margin
- 87.7%
- Us glaucoma net sales
- 118600000
- Us glaucoma growth yoy
- 47%
- Corneal health net sales
- 59000000
- Corneal health growth yoy
- 154%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.